Evidence map›Paper›PMID 32661629›Full record

ArticleInternational urology and nephrology2020

Arylesterase activity but not PCSK9 levels is associated with chronic kidney disease in type 2 diabetes.

Nutsiwat Didas, Witsawat Thitisopee, Sureerut Porntadavity, Nutjaree Jeenduang

Abstract read
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Nutsiwat DidasSchool of Allied Health Sciences, Walailak University, 222 Thaiburi, Thasala, Nakhon Si Thammarat, Thailand.
Witsawat ThitisopeeDepartment of Medicine, Thasala Hospital, Nakhon Si Thammarat, Thailand.
Sureerut PorntadavityDepartment of Clinical Chemistry, Faculty of Medical Technology, Mahidol University, Bangkok, Thailand.
Nutjaree JeenduangSchool of Allied Health Sciences, Walailak University, 222 Thaiburi, Thasala, Nakhon Si Thammarat, Thailand. nutjaree.je@wu.ac.th.ORCID http://orcid.org/0000-0002-1597-5666
Walailak University · THMahidol University · THNakhon Si Thammarat Rajabhat University · TH

Funding

Graduate Student Research Grant No. 08/2562Walailak University Fund WU-IRG-62-020
6 · The paper itself

Abstract

purposeOxidative stress and dyslipidemia have been found to be associated with the progression of chronic kidney disease (CKD) in type 2 diabetes mellitus (T2DM) patients. Paraoxonase 1 (PON-1) activity, and proprotein convertase subtilisin kexin type 9 (PCSK9) levels play an important role regarding anti-oxidants, and lipid metabolism, respectively. The aim of this study was to investigate the association of PON-1 activity, and PCSK9 levels with CKD in T2DM.

methodsA total of 180 T2DM (87 CKD, and 93 non-CKD) with age-, and gender-matched subjects were recruited in this study. PON-1 activity was measured with two kinds of substrate: paraoxon for paraoxonase (PONase) activity and phenylacetate for arylesterase (AREase) activity. PCSK9 levels were measured by enzyme-linked immunosorbent assay (ELISA).

resultsAREase activity was significantly lower in CKD compared with non-CKD (225.53 ± 108.73 vs. 257.45 ± 106.12 kU/L, p = 0.044) in T2DM, whereas there was no significant difference in PONase activity and PCSK9 levels between CKD and non-CKD groups. In addition, multivariate logistic regression analysis showed that the lowest tertile of AREase increased the risk for CKD in T2DM (OR 3.251; 95% CI 1.333-7.926, p = 0.010), whereas PONase activity and PCSK9 levels were not associated with CKD in T2DM.

conclusionReduced AREase activity can increase the risk for CKD in T2DM patients. AREase activity, but not PONase activity and PCSK9 levels, may be used as the biomarker for predicting the progression of CKD in T2DM.

Indexed as

AgedAryldialkylphosphataseCarboxylic Ester HydrolasesCross-Sectional StudiesDiabetes ComplicationsDiabetes Mellitus, Type 2FemaleHumansMaleMiddle AgedProprotein Convertase 9Renal Insufficiency, ChronicAryldialkylphosphatasearylesteraseCarboxylic Ester HydrolasesPCSK9 protein, humanPON1 protein, humanProprotein Convertase 9CKDNon-CKDParaoxonase 1PCSK9Type 2 diabetes

Identifiers

PMID32661629
OpenAlexW3042845078

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.